Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) Reported Basic Consolidated EPS Of $-0.3995

0

For the period ended 2015-06-30, Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) reported $-0.3995 as the annual basic consolidated EPS. On quarterly basis, $-0.3995 was captured as the basic consolidated EPS reading for the quarter ended 2015-06-30.

EPS from continuing operations

For the annual period ended 2015-06-30 and in line with the basic EPS from continuing operations Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) reported $-0.3995. For the three-month period ended 2015-06-30, quarterly basis EPS from continuing operations stood at $-0.3995.

EPS contribution from parent

Basic EPS received by Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) from its parent company was $-0.3995 for the annual period ended 2015-06-30. For the period ended 2015-06-30, the quarterly basis the basic EPS contribution from the parent company was $-0.3995.

Basic net EPS

Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) reported basic net EPS of $-0.3783 for the annual period ended 2015-06-30. The company’s basic net EPS on a quarterly basis stood at $-0.3783 for the three-month period ended 2015-06-30.

Consolidated diluted EPS

The period ended 2015-06-30 had an annual consolidated diluted EPS reading of $-0.3995. Consolidated diluted EPS for the quarter ended 2015-06-30 was $-0.3995.

b>Basic diluted EPS

For the period ended 2015-06-30 diluted EPS reading from continuing operation on annual basis was $-0.3995. However, $-0.3995 was registered as the Diluted EPS from continuing operations for the quarter ended 2015-06-30.

Net diluted EPS

For the annual period ended 2015-06-30, $-0.3783 was the Net diluted EPS reading. But the quarterly period that ended 2015-06-30, net diluted EPS was $-0.3783.

Diluted EPS from parent

Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) received diluted EPS of $-0.3995 from the parent company which was for the annual period ended 2015-06-30. However, on quarterly basis, $-0.3995 was the diluted EPS contribution from the parent for the quarter ended 2015-06-30. The net basic EPS reading of $-0.42 was posted by Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) which was representing the annual period ended 2015-06-30. Basic net EPS of $-0.42 was for the quarter ended 2015-06-30.

For the annual period ended 2015-06-30, Net diluted EPS was $-0.42 for the annual period ended 2015-06-30. There was also a report by the company of $-0.42 being the net diluted EPS reading for the quarter ended 2015-06-30.

While the shares for the quarter ended 2015-06-30 were at 70.785, the period ended 2015-06-30 is 70.785 being the annual average basic shares outstanding.

For the fiscal year ended is 2015-06-30 while 70.785 represents the quarter ended 2015-06-30.

1 Chart Pattern Every Investor Should Know

This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...

Click Here to See This Now.

(Visited 27 times, 1 visits today)